Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) – Equities researchers at William Blair boosted their Q3 2017 earnings per share (EPS) estimates for Eagle Pharmaceuticals in a research report issued on Wednesday. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will post earnings of $0.76 per share for the quarter, up from their previous forecast of $0.57. William Blair also issued estimates for Eagle Pharmaceuticals’ Q4 2017 earnings at $0.92 EPS and FY2018 earnings at $3.52 EPS.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.51 by $0.18. Eagle Pharmaceuticals had a return on equity of 66.30% and a net margin of 39.32%. The business had revenue of $50.10 million during the quarter, compared to analysts’ expectations of $52.52 million. During the same quarter in the previous year, the company posted $0.80 EPS. The company’s quarterly revenue was up 22.5% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/16/eagle-pharmaceuticals-inc-to-post-q3-2017-earnings-of-0-76-per-share-william-blair-forecasts-egrx.html.

EGRX has been the subject of a number of other reports. Piper Jaffray Companies set a $118.00 target price on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, July 25th. BidaskClub downgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, July 31st. Royal Bank Of Canada set a $94.00 target price on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, July 16th. Zacks Investment Research downgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, July 31st. Finally, Mizuho decreased their target price on shares of Eagle Pharmaceuticals from $57.00 to $40.00 and set an “underperform” rating for the company in a research report on Thursday, July 27th. Three analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $75.40.

Shares of Eagle Pharmaceuticals (EGRX) opened at 54.10 on Monday. Eagle Pharmaceuticals has a 52 week low of $45.05 and a 52 week high of $97.15. The stock has a market cap of $820.64 million, a price-to-earnings ratio of 9.08 and a beta of 1.31. The firm has a 50-day moving average price of $65.84 and a 200-day moving average price of $76.01.

Several hedge funds and other institutional investors have recently modified their holdings of the company. State of Alaska Department of Revenue increased its position in shares of Eagle Pharmaceuticals by 78.9% in the second quarter. State of Alaska Department of Revenue now owns 1,592 shares of the specialty pharmaceutical company’s stock worth $125,000 after buying an additional 702 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Eagle Pharmaceuticals by 15.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,548 shares of the specialty pharmaceutical company’s stock worth $128,000 after buying an additional 202 shares during the period. Municipal Employees Retirement System of Michigan increased its position in shares of Eagle Pharmaceuticals by 6.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 120 shares during the period. Mason Street Advisors LLC increased its position in shares of Eagle Pharmaceuticals by 10.2% in the first quarter. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company’s stock worth $157,000 after buying an additional 175 shares during the period. Finally, Bank of Montreal Can increased its position in shares of Eagle Pharmaceuticals by 323.9% in the second quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 1,908 shares during the period.

In other news, CFO Pete A. Meyers acquired 350 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was acquired at an average price of $71.49 per share, for a total transaction of $25,021.50. Following the completion of the transaction, the chief financial officer now owns 350 shares in the company, valued at approximately $25,021.50. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Douglas L. Braunstein acquired 20,400 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was purchased at an average price of $49.07 per share, with a total value of $1,001,028.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 21,005 shares of company stock valued at $1,046,370. Insiders own 19.50% of the company’s stock.

Eagle Pharmaceuticals declared that its Board of Directors has authorized a share repurchase program on Wednesday, August 9th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the specialty pharmaceutical company to buy up to 13.3% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Earnings History and Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.